Heal Capital

What they fund

Early-stage digital health startups across Europe, specifically those building software, AI-driven tools, and care delivery platforms [1]. They fund ventures that improve healthcare access and efficiency, excluding therapeutic or drug development [1].

Investment thesis

HEAL Capital backs founders building the next generation of market-leading healthcare platforms across Europe, focusing on digital health, AI, and software that transforms how healthcare operates [1]. They target solutions ranging from care delivery tools and patient apps to health system infrastructure, explicitly excluding drugs or therapeutic candidates [1]. The firm leverages its network to connect founders with customers, key opinion leaders, and partners to generate revenue [1]. Their strategy is to lead or co-lead investments in early-stage ventures that combine data-driven technology with deep healthcare expertise, aiming to scale solutions that improve patient outcomes and operational efficiency [1].

Credibility: The firm's homepage and investment criteria explicitly state these focus areas and exclusions [1].

Value add

The firm leverages its network to connect founders with customers, key opinion leaders, and partners to generate revenue [1].

Fit verdict: Ideal for founders needing strategic introductions and early-stage capital in digital health.

Founder diligence script:

• What specific KOLs or healthcare partners can you introduce me to in my first 12 months?
• How do you structure your follow-on investments for successful seed companies?
• What is your typical timeline for due diligence and term sheet issuance?

Portfolio focus

• Healthcare Infrastructure — Companies like Siilo (medical communication network) and Medishout (hospital-supplier operations)., - AI Diagnostics & Clinical Tools — Firms like Gleamer (AI radiology), Hypervision (surgical imaging), and CereGate (brain-computer interfaces)., - Patient-Centric Platforms — Apps like Ditto (medical appointment management) and Paloma Health (specialist care access)., - Operational & B2B HealthTech — Solutions like Praxisflow (practice management), Parto (care institution payments), and PeakData (pharma insights).

Notable investments & exits

• Siilo — Acquired by Doctolib., - Formel Skin — Exited., - Infermedica — Exited., - Entyre — Exited., - Medicilio — Exited.

Strategic implications

The firm's explicit exclusion of drugs and focus on software/AI positions it as a pure-play enabler in the digital health value chain, avoiding the high risk and long timelines of biotech. Their emphasis on connecting founders with customers and KOLs suggests a strong operational focus, which is critical for early-stage healthcare startups that often struggle with commercialization. The firm's edge lies in its ability to de-risk early-stage investments through strategic network access, making it a valuable partner for founders navigating complex healthcare markets.

Where they could go further

The firm could enhance its value proposition by establishing a formalized mentorship program with experienced healthcare executives to help founders navigate regulatory landscapes. Expanding its network to include international healthcare systems could provide founders with broader commercialization opportunities beyond Europe. Developing a dedicated fund for follow-on investments would allow the firm to support its most successful portfolio companies through later stages, capturing more value.